Abrogation of tumor rejection by trypan blue.
Trypan blue treatment prevented tumor-specific rejection in three animal model systems. These included the spontaneous rejection of tumors of mice (UVT-2051) and guinea pig (line 1 hepatoma) as well as vaccine-induced rejection of a guinea pig tumor (line 10 hepatoma). Secondary immune reactions to line 10 cell challenges were not abolished by trypan blue treatment. Although trypan blue is a potent inhibitor of macrophage cytotoxicity in vitro, the mechanism by which it inhibited tumor-specific rejection has not been established.
D000818:Animals; D000831:Animals, Newborn; D000951:Antigens, Neoplasm / Q000008:administration & dosage; D006528:Carcinoma, Hepatocellular / Q000276:immunology; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006084:Graft Rejection / Q000187:drug effects*; D006168:Guinea Pigs; D007165:Immunosuppression Therapy; D008113:Liver Neoplasms / Q000276:immunology; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000276:immunology*; D014184:Transplantation, Homologous; D014343:Trypan Blue / Q000494:pharmacology*
D000951:Antigens, Neoplasm; D014343:Trypan Blue